8-K: Synaptogenix Executes 1-for-25 Reverse Stock Split to Regain Nasdaq Compliance

Synaptogenix has completed a 1-for-25 reverse stock split to increase its share price and maintain its Nasdaq listing.

Summary

• Synaptogenix, Inc. has implemented a 1-for-25 reverse stock split of its common stock.
• The reverse stock split became effective at 5:00 p.m. Eastern Time on April 4, 2024.
• Every 25 shares of common stock were converted into one share.
• The reverse stock split was undertaken to increase the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement.
• The number of outstanding shares decreased from 27,133,349 to approximately 1,085,333, subject to adjustment for fractional shares.
• Proportional adjustments were made to stock options, warrants, and other convertible securities.
• Stockholders who would have received fractional shares will receive a cash payment based on the closing price on April 4, 2024, adjusted for the split.
• The stock will continue to trade on the Nasdaq under the symbol SNPX, with the new CUSIP number 87167T300.

Sentiment

Score: 5

Explanation: The document is neutral, detailing a necessary corporate action to maintain listing compliance. While not inherently positive, it is a step to avoid delisting.

Positives

• The reverse stock split is intended to help Synaptogenix maintain its listing on the Nasdaq Capital Market.
• The company has taken action to address the minimum bid price requirement.

Negatives

• The reverse stock split reduces the number of outstanding shares, which can be perceived negatively by some investors.
• The need for a reverse stock split indicates that the company's share price was below the Nasdaq minimum bid price.

Risks

• The company's ability to maintain compliance with Nasdaq listing requirements is not guaranteed.
• The company's future success depends on the clinical development and commercialization of its drug candidates.
• The company faces risks related to obtaining adequate financing, regulatory approvals, and competition.

Future Outlook

The company intends to maintain its Nasdaq listing and continue the development of its therapeutic candidates.

Industry Context

Reverse stock splits are a common mechanism for companies to regain compliance with stock exchange listing requirements, particularly for companies in the biotechnology sector that may experience stock price volatility.

Comparison to Industry Standards

• Reverse stock splits are a common practice among companies facing delisting from major exchanges like Nasdaq.
• Many small-cap biotech companies have used reverse stock splits to maintain listing compliance, such as Agenus Inc. (AGEN) and Cassava Sciences, Inc. (SAVA).
• The 1-for-25 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-100 depending on the company's specific situation.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same, except for fractional shares.
• The reverse stock split is intended to benefit shareholders by maintaining the company's Nasdaq listing.

Next Steps

• The company will continue to trade on the Nasdaq under the symbol SNPX.
• The company will continue to develop its therapeutic candidates.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, SNPX, stock compliance, Synaptogenix, share price, biopharmaceutical